NLSP 6-K: press release on Kadimastem–TargetGene collaboration

Rhea-AI Filing Summary

NLS Pharmaceutics Ltd. furnished a Form 6-K announcing it issued a press release titled “NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies.”

The press release, dated October 27, 2025, is included as Exhibit 99.1. The filing lists the company’s principal executive office at The Circle 6, 8058 Zurich, Switzerland and cites Commission File Number 001-39957.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2025 (Report No. 4)

Commission File Number: 001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

CONTENTS

On October 27, 2025, NLS Pharmaceutics Ltd. issued a press release titled: “NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies.” A copy of this press release is furnished herewith as Exhibit 99.1.

EXHIBIT INDEX

Exhibit Number		Description of Document
99.1		Press release titled: “NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies.”

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NLS Pharmaceutics Ltd.
Date: October 27, 2025	By:	/s/ Alexander C. Zwyer
		Name:	Alexander C. Zwyer
		Title:	Chief Executive Officer

2

FAQ

What did NLS Pharmaceutics (NLSP) report in this Form 6-K?

It furnished a press release titled “NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies.”

When was the press release issued by NLSP?

October 27, 2025.

Which exhibit contains the press release in NLSP’s 6-K?

Exhibit 99.1.

What is the subject of the press release mentioned by NLSP?

A strategic collaboration between Kadimastem and TargetGene to advance next-generation gene-edited cell therapies.

What is NLS Pharmaceutics’ Commission File Number?

001-39957.

Where is NLS Pharmaceutics’ principal executive office located?

The Circle 6, 8058 Zurich, Switzerland.